Drug Type Autologous CAR-T |
Synonyms- |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD22 inhibitors(CD22 inhibitors), Gene transference |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Lymphoma | Phase 1 | CN | - | 08 Oct 2019 |
CD19 positive Acute Lymphoblastic Leukemia | Phase 1 | CN | - | 08 Oct 2019 |
CD19 Positive Lymphoma | Phase 1 | CN | - | 08 Oct 2019 |
CD22 positive Acute Lymphoblastic Leukemia | Phase 1 | CN | - | 08 Oct 2019 |
CD22 positive lymphoma | Phase 1 | CN | - | 08 Oct 2019 |